{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:03:12Z","timestamp":1785438192002,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T00:00:00Z","timestamp":1472256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T00:00:00Z","timestamp":1472256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10637-016-0382-3","type":"journal-article","created":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T00:26:07Z","timestamp":1472257567000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Phase Ia\/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Noboru","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yanagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyasu","family":"Inatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,27]]},"reference":[{"key":"382_CR1","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-09-3004","volume":"16","author":"MS Van Der Heijden","year":"2010","unstructured":"Van Der Heijden MS, Bernards R (2010) Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 16:3094\u20133099","journal-title":"Clin Cancer Res"},{"key":"382_CR2","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1021\/jm800295d","volume":"51","author":"AJ Folkes","year":"2008","unstructured":"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51:5522\u20135532","journal-title":"J Med Chem"},{"key":"382_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"SM Maira","year":"2012","unstructured":"Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Ch\u00e8ne P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garc\u00eda-Echeverr\u00eda C, Sellers WR, Voliva CF (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11:317\u2013328","journal-title":"Mol Cancer Ther"},{"key":"382_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1158\/1078-0432.CCR-13-1777","volume":"20","author":"GI Shapiro","year":"2014","unstructured":"Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Bra\u00f1a I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G (2014) Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20:233\u2013245","journal-title":"Clin Cancer Res"},{"key":"382_CR5","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1158\/1535-7163.MCT-08-1200","volume":"8","author":"FI Raynaud","year":"2009","unstructured":"Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8:1725\u20131738","journal-title":"Mol Cancer Ther"},{"key":"382_CR6","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-11-2088","volume":"18","author":"JJ Wallin","year":"2012","unstructured":"Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, Koeppen H, Belvin M, Friedman LS, Sampath D (2012) GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res 18:3901\u20133911","journal-title":"Clin Cancer Res"},{"key":"382_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","volume":"21","author":"D Sarker","year":"2015","unstructured":"Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS (2015) First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21:77\u201386","journal-title":"Clin Cancer Res"},{"key":"382_CR8","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"382_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2011.12.005","volume":"76","author":"Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group","year":"2012","unstructured":"Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76:362\u2013367","journal-title":"Lung Cancer"},{"key":"382_CR10","first-page":"503","volume":"5","author":"ZQ Zou","year":"2012","unstructured":"Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ, Zhang XH (2012) The novel dual PI3K\/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol Med Rep 5:503\u2013508","journal-title":"Mol Med Rep"},{"key":"382_CR11","first-page":"3044","volume":"29","author":"B Besse","year":"2011","unstructured":"Besse B, Soria J, Ware J, Adjei AA, Dy GK, Shankar G, Brachmann RK, Groen HJ (2011) A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011 ASCO Annu Meet Abstr Part 1 29:3044","journal-title":"J Clin Oncol 2011 ASCO Annu Meet Abstr Part 1"},{"key":"382_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1. Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"382_CR13","unstructured":"Besse B, Luft AV, Fadeeva N, Mezger J, Beck T, Bidoli P, Denis F, Paschold E, Robinet G, Groen H, Pawel JV, Lackner M, Gendreau S, Spoerke J, Bassett K, Koeppen H, Gilbert H, Jin H, Shankar G, Lin W, Felip E (2015) A phase II trial of pictilisib with chemotherapy in first-line non-squamous NSCLC. In: 16th World Conf. Lung Cancer. MINI30.12"},{"key":"382_CR14","unstructured":"Spigel DR, Luft A, Vynnychenko I, Fadeeva N, Mark Z, Ponce S, Matrosova M, Goldschmidt J, Szima B, Saleh M, Lackner M, Gendreau S, Bassett K, Spoerke J, Koeppen H, Gilbert H, Jin H, Shankar G, Lin W, Denis F (2015) A phase II trial of pictilisib with chemotherapy in first-line squamous NSCLC. In: 16th World Conf. Lung Cancer. MINI30.13"},{"key":"382_CR15","unstructured":"Dy GK, Adjei A, Groen HJM, Ware JA, Shankar G, Lin W, Besse B, Bahleda, R, Planchard D, Soria J (2013) A Phase Ib, open label, dose escalation study of the safety and pharmacology of PI3-Kinase (PI3K) Inhibitor GDC 0941 in combination with either Paclitaxel (Pac) and Carboplatin (Carbo) with or without Bevacizumab (Bev), or Pemetrexed (Pem), Cisplatin (Cis). 15th World Conf. Lung Cancer"},{"key":"382_CR16","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543\u20133551","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-016-0382-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0382-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:00:44Z","timestamp":1678510844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-016-0382-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1007\/s10637-016-0382-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,27]]},"assertion":[{"value":"31 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was supported by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Medical writing assistance and editing was provided by Macmillan Medical Communications (Tokyo, Japan), and funded by Chugai Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Noboru Yamamoto has received research grants from Chugai Pharmaceutical, Eli Lilly, Taiho, Eisai, Quintiles, Astellas Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, Boehringer-Ingelheim, Kyowa-Hakko Kirin, and Bayer.Yutaka Fujiwara has received research grants from AstraZeneca, Daiichi Sankyo, Chugai Pharmaceutical, Eisai, Eli Lilly, MSD, and Merck Serono.Kenji Tamura has received research grants from Chugai Pharmaceutical, AstraZeneca, Daiichi Sankyo, Eisai, MSD, Eli Lilly, Pfizer, AbbVie and Byer.Shunsuke Kondo has received research grants from Bayer, AstraZeneca, and Eli Lilly.Satoru Iwasa has no conflicts of interest to declare.Yuko Tanabe has no conflicts of interest to declare.Atsushi Horiike has no conflicts of interest to declare.Noriko Yanagitani is an advisory board member of Chugai Pharmaceutical.Satoru Kitazono has no conflicts of interest to declare.Michiyasu Inatani and Jun Tanaka are employee of Chugai Pharmaceutical.Makoto Nishio has received research grants from Novartis, Ono Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, Eli Lilly, Pfizer, Astellas Pharma, and AstraZeneca, and honoraria from Pfizer, Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, and AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the Pharmaceutical Affairs Law, and Good Clinical Practice. The study protocol was approved by the Institutional Review Boards of the participating institutions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Written informed consent was obtained from all patients included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}